AVAI (Avai Bio) 1-Year Sharpe Ratio: -0.80 (As of Jul. 04, 2026)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.13
! 3 Warning Signs
View Full Analysis

What is Avai Bio 1-Year Sharpe Ratio?

Avai Bio AVAI +5.80% 24 1-Year Sharpe Ratio is -0.80 as of Jul. 04, 2026. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-04), Avai Bio's 1-Year Sharpe Ratio is -0.80.

Avai Bio  (OTCPK:AVAI) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.

Avai Bio 1-Year Sharpe Ratio Related Terms

AVAI vs IPM, RCT, LPSN: 1-Year Sharpe Ratio Comparison

For the Software - Application subindustry, Avai Bio's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avai Bio 1-Year Sharpe Ratio vs Software Industry

For the Software industry and Technology sector, Avai Bio's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Avai Bio's 1-Year Sharpe Ratio falls into.


AVAI
24GF Score
Avai Bio Inc AVAI
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.80 mean?
Avai Bio (AVAI) has a 1-Year Sharpe Ratio of -0.80 as of Jul. 04, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Avai Bio and its competitors.
Is Avai Bio's 1-Year Sharpe Ratio too high?
Avai Bio's current 1-Year Sharpe Ratio is -0.80. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's 1-Year Sharpe Ratio compare to IPM and RCT?
Avai Bio's 1-Year Sharpe Ratio of -0.80 can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Software company?
A good 1-Year Sharpe Ratio depends on the Software industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Avai Bio and its competitors. Avai Bio's current 1-Year Sharpe Ratio is -0.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current 1-Year Sharpe Ratio of -0.80. The current 1-Year Sharpe Ratio is -0.80. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Avai Bio (AVAI), the current 1-Year Sharpe Ratio is -0.80 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price